Genitourinary medical oncology
BA: Northwestern University, 1981; PhD: University of Chicago, 1988; MD: University of Chicago Pritzker, 1989. Resident: University of California Los Angeles (UCLA) Medical Center, 1990-1993; Hematology-Oncology Fellow: UCLA Medical Center, 1993-1996; Postdoctoral Fellow: UCLA, 1996-1998; Assistant Professor: University of North Carolina, 1998-2005; Associate Professor: University of North Carolina, 2005-present.
Research and Clinical Interests
My laboratory is interested in characterizing the role of cytoplasmic signaling pathways in regulation of androgen receptor activity and progression of prostate cancer. Our studies have focused on HER-2 receptor tyrosine kinase and we have demonstrated that HER-2 activation stimulates androgen receptor activity and HER-2 inhibition inhibits androgen receptor transcriptional function at the level of recruitment to the androgen responsive enhancers. These findings have led to the design and initiation of the protocol involving lapatinib, a clinical HER-2 inhibitor, in treatment of patients with prostate cancer. More recently, we have demonstrated that activated Cdc42-associated kinase Ack1 promotes progression of prostate cancer via tyrosine phosphorylation of androgen receptor at Tyr-267 and Tyr-363 residues. We are interested in further characterizing the role of tyrosine phosphorylation of androgen receptor in prostate cancer and development of Ack1 targeted therapy for clinical use.